An injection is the ideal administration route for pain, ligament damage, inflammation, and muscle sprains
However, further studies are still needed to optimize its clinical application, including dosage form improvement, combination therapy strategies and long-term safety assessment
Who is most at risk
investigational, with no approved human indication
Reclassification is not supposed to be a route for unapproved drugs to get into the market, Janet Woodcock, a former FDA chief deputy commissioner who helped oversee the 2023 assignment of the peptides to category two due to safety concerns, told ProPublica before the meeting
There is no preparation, no downtime, and no recovery